Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28677470 | 0.97 | CYP2C19 (0.56) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL25533017 | 0.94 | CYP2C19 (0.51) | CYP3A4CYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL7409492 | 0.87 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL7412438 | 0.87 | CYP3A4 (0.54) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL12606879 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL24707932 | 0.81 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL25597428 | 0.81 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL304701 | 0.81 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL27564114 | 0.81 | CYP3A4 (0.52) | CYP3A4CYP2C9CYP2C19ALDH1A1EPHX1 | |
| SCHEMBL11372657 | 0.80 | CYP2C19 (0.50) | CYP3A4CYP2C9CYP2C19ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577325-B2 | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof | SYSTIMMUNE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250205349-A1 | ANTI-HUMAN TROP2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND MEDICAL USE THEREOF | SYSTIMMUNE, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-120131991-A | Anti-human Claudin18.2 antibody-camptothecine drug conjugate and medical application thereof | 成都百利多特生物药业有限责任公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250115679-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. (CN) | 2025-04-10 | — | — | US | disclosed |
| US-20250059296-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | SYSTIMMUNE INC (US) | 2025-02-20 | — | — | US | disclosed |
| CN-117752813-A | anti-CD 33 antibodies and anti-CD 33 antibody-drug conjugates and uses thereof | 成都百利多特生物药业有限责任公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116212044-A | Anti-human Trop2 antibody-camptothecin drug conjugate and medical application thereof | 成都百利多特生物药业有限责任公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116120460-A | Bispecific antibody-camptothecins drug conjugate and medical application thereof | 成都百利多特生物药业有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-113827736-A | Camptothecin drug with high-stability hydrophilic connecting unit and conjugate thereof | 四川百利药业有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577325-B2 | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof | IGLV6-57, EGFR, ERBB2 | CYP3A4 2638/4885CYP2C9 1969/4885CYP2C19 2353/4885 |
| US-20250115679-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | ANTXR2, PAICS, CD38 | CYP3A4 2614/4885CYP2C9 1940/4885CYP2C19 1716/4885 |
| US-20250059296-A1 | BISPECIFIC ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | ANTXR2, PAICS, CD38 | CYP3A4 2614/4885CYP2C9 1940/4885CYP2C19 1716/4885 |
| US-20250205349-A1 | ANTI-HUMAN TROP2 ANTIBODY-CAMPTOTHECIN DRUG CONJUGATE AND MEDICAL USE THEREOF | TOP2A, TPM4, TPM3 | CYP3A4 2271/4885CYP2C9 2474/4885CYP2C19 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.